Disitamab Vedotin (RC48) Clinical Trials

3 actively recruiting trials

No change since May 2026

Also known as: RC48

Pipeline

Phase 2: 3

Top Sponsors

The First Affiliated Hospital with Nanjing Medical University2
Fudan University1

Indications

Cancer3
Breast Cancer2
HER2 + Breast Cancer1
HER2-low Breast Cancer1
Gastric Cancer1

Other3 trials

Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer

Phase 2

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.